CAS: 135-07-9; Methyclothiazide

该化合物是一种硫酸二甲酯,通常用于治疗高血压和水肿.它的作用是抑制钠重新吸附于丙烯的溶解管管管,导致钠和水的排泄增加,从而减少血量和血压.甲草胺的化学配方是C8H9ClN2O4S,它具有一种硫酸盐环状结构,这是该类二尿素的特征.该物质通常以白色的形式呈现给非白晶状晶粉,在水中略有溶解,有机溶剂的溶性较高.甲草胺酯具有中度的半衰期,允许在临床实践中一次性使用.它的药理效应可能导致电解不平衡,特别是低血糖,在治疗期间需要监测钾水平.此外,它可能与其他药物发生相互作用,因此仔细考虑病人的总体抗压剂和高血压剂的保存是关键因素.

结构式图片

上下游产品

CAS号121-30-2 4-氨基-6-氯-1,3-苯二磺酰胺 | CAS号89813-56-9 4-chloro-10-hyd... | CAS号107-20-0 一氯乙醛

合成工艺路线路线简述

    氢氯噻嗪杂质n置于sodium Hydroxide,Sodium Hydride体系中,用 水,N,N-二甲基甲酰胺 用作溶剂,化学反应 1.0H,反应生成甲氯噻嗪
    参考文献:Synthesis Of Potential Diuretic Agents. I. Derivatives Of 7-Sulfamyl-3,4-Dihydro-1,2,4-Benzothiadiazine 1,1-Dioxide
    标题:Synthesis Of Potential Diuretic Agents. I. Derivatives Of 7-Sulfamyl-3,4-Dihydro-1,2,4-Benzothiadiazine 1,1-Dioxide
    摘要:
    Doi:10.1021/ja01490A028

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10973847-B2
    优先权日:2017-06-30
    标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
    发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-2024368164-A1
    优先权日:2021-04-28
    标 题 :Purine nucleosides, their intermediates, and methods of preparation thereof
    发明人:RAVI RAMA SURESH; JACOBSON KENNETH A; POE RUSSELL BIRCH
    权利人:ASTROCYLE PHARMACEUTICALS INC; US HEALTH
    摘要:The present invention provides purine nucleoside analog compounds and methods of use thereof for treatment of certain injuries, disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries. The present invention further provides methods of synthesizing such compounds, and intermediates useful in the synthesis of such compounds.

    专利号:US-2008090885-A1
    优先权日:2006-10-12
    标题:Preparation of losartan 5-carboxylic acid and use thereof
    发明人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    权利人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    摘要:A method for synthesis of losartan 5-carboxylic acid (EXP-3174).
    辽宁海德制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.haide-chem.com
    企业联系电话:0414-2521668,2521696👤
    📞辽宁海德制药有限公司 ⚠️参考联系方式

    电话:0414-2521668,2521696

    传真:0414-2521689
    邮箱:reser@haide-chem.com
    通信地址: 辽宁省本溪市北台工业园区
    邮编: 117017
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:辽宁省本溪市北台工业园区
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shimizu H, Nagami S, Takahashi N. [A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in which lomerizine hydrochloride was suggested to prevent recurrent stroke]. Rinsho Shinkeigaku. 2014;54(1):22-6. Japanese.
    6: Black HR, Chrysant SG, Curry CL, Frishman WH, Grimm RH, Lasseter KC, Okun R, Pool JL, Raizada V, Vlachakis ND, et al. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol. 1992 Apr;32(4):351-9. Japanese. Japanese. Spanish. Danish.

    合成参考文献


    参考文献:10.1007/s00216-010-3484-3
    摘要:Peters RJB, Oosterink JE, Stolker AAM, Georgakopoulos C, Nielen MWF. Generic sample preparation combined with high-resolution liquid chromatography–time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. Analytical and Bioanalytical Chemistry. 2010 Feb 16;396(7):2583–98. doi: 10.1007/s00216-010-3484-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知